This review discusses the rational for further studies of COX-2 inhibitors-NO releaser hybrids (NO-Coxibs) in the pharmacological treatment of the airway inflammation in Cystic Fibrosis (CF). Our research group developed several classes of NO-Coxibs for the pharmacological treatment of arthritis, and among them several compounds showed an outstanding in vivo efficacy and good pharmacokinetic properties. The good antiinflammatory properties displayed by these compounds during the previous screening could, by itself, suggest appropriate candidates for further testing in CF.

中文翻译：

---

囊性纤维化中Coxibs-一氧化氮释放杂种的治疗潜力

这篇综述讨论了在囊性纤维化（CF）气道炎症的药物治疗中进一步研究COX-2抑制剂-NO释放杂种（NO-Coxibs）的合理性。我们的研究小组开发出了几类用于关节炎药理治疗的NO-Coxibs，其中几种化合物表现出出色的体内功效和良好的药代动力学特性。这些化合物在先前的筛选过程中表现出的良好的抗炎特性本身可以为进一步在CF中进行检测提供合适的候选药物。